Kinnate Biopharma (KNTE)

Kinnate Biopharma (KNTE) Stock Price & Analysis


KNTE Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$2.32 - $15.86
Previous Close$3.73
Average Volume (3M)404.58K
Market Cap
Enterprise Value-$23.32M
Total Cash (Recent Filing)$200.98M
Total Debt (Recent Filing)$3.95M
Price to Earnings (P/E)-1.4
Aug 14, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.75
Shares Outstanding46,572,594
10 Day Avg. Volume372,441
30 Day Avg. Volume404,579
Standard Deviation0.26
Financial Highlights & Ratios
Price to Book (P/B)8.10
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.18
Price Target Upside357.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Kinnate Biopharma’s price range in the past 12 months?
Kinnate Biopharma lowest stock price was $2.32 and its highest was $15.86 in the past 12 months.
    What is Kinnate Biopharma’s market cap?
    Currently, no data Available
    When is Kinnate Biopharma’s upcoming earnings report date?
    Kinnate Biopharma’s upcoming earnings report date is Aug 14, 2023 which is in 78 days.
      How were Kinnate Biopharma’s earnings last quarter?
      Kinnate Biopharma released its earnings results on May 11, 2023. The company reported -$0.73 earnings per share for the quarter, missing the consensus estimate of -$0.711 by -$0.019.
        Is Kinnate Biopharma overvalued?
        According to Wall Street analysts Kinnate Biopharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Kinnate Biopharma pay dividends?
          Kinnate Biopharma does not currently pay dividends.
          What is Kinnate Biopharma’s EPS estimate?
          Kinnate Biopharma’s EPS estimate is -$0.75.
            How many shares outstanding does Kinnate Biopharma have?
            Kinnate Biopharma has 46,572,594 shares outstanding.
              What happened to Kinnate Biopharma’s price movement after its last earnings report?
              Kinnate Biopharma reported an EPS of -$0.73 in its last earnings report, missing expectations of -$0.711. Following the earnings report the stock price went up 5.307%.
                Which hedge fund is a major shareholder of Kinnate Biopharma?
                Among the largest hedge funds holding Kinnate Biopharma’s share is RA Capital Management. It holds Kinnate Biopharma’s shares valued at 27M.


                  Kinnate Biopharma Stock Smart Score

                  The Kinnate Biopharma stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Kinnate Biopharma

                  Kinnate Biopharma Inc a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. The company's product candidate is KIN002787, which is a Rapidly Accelerated Fibrosarcoma (RAF) inhibitor it is developing for the treatment of patients with lung cancer, melanoma and other solid tumors. Its KIN003 program is evaluating Fibroblast Growth Factor Receptors (FGFR) inhibitor candidates for the treatment of patients with intrahepatic cholangiocarcinoma (ICC), a cancer of the bile ducts in the liver, and urothelial carcinoma (UC), a cancer of the bladder lining.


                  Top 5 ETFs holding KNTE

                  Market Value
                  Smart Score
                  iShares NASDAQ US Biotechnology UCITS ETF
                  Invesco Nasdaq Biotechnology ETF
                  Up to five ETFs with an Outperform Smart Score that hold KNTE. The ETFs are listed according to market value of KNTE within the ETF


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  MiMedx Group
                  Organogenesis Holdings
                  PepGen Inc.

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis